Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: invIOs
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/16/2024 |
News Article |
invIOs to present progress across oncology pipeline during JP Morgan Week 2025 |
|
10/15/2024 |
News Article |
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology |
|
12/21/2023 |
News Article |
invIOs to attend JP Morgan Week in San Francisco in January |
|
09/05/2023 |
News Article |
invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding |